Chemo-informatics activity prediction, ligand based drug design, Molecular docking and pharmacokinetics studies of some series of 4, 6-diaryl-2-pyrimidinamine derivatives as anti-cancer agents
The first model was selected as the best because of its fitness statistically with the following assessment parameters: R2train = 0.832, R2adj = 0.79, R2ext = 0.62, Q2 = 0.68, and LOF = 0.14509. Compound 11 was selected as a template to design new powerful compounds based on its low residual and hig...
Lưu vào:
Tác giả chính: | Abdullahi, Sagiru Hamza |
---|---|
Đồng tác giả: | Uzairu, Adamu |
Định dạng: | BB |
Ngôn ngữ: | en_US |
Thông tin xuất bản: |
2023
|
Chủ đề: | |
Truy cập trực tuyến: | http://tailieuso.tlu.edu.vn/handle/DHTL/12517 |
Từ khóa: |
Thêm từ khóa bạn đọc
Không có từ khóa, Hãy là người đầu tiên gắn từ khóa cho biểu ghi này!
|
Tài liệu tương tự
-
Theoretical activity prediction, structure-based design, molecular docking and pharmacokinetic studies of some maleimides against Leishmania donovani for the treatment of leishmaniasis
Thông tin tác giả:: Ugbe, Fabian Audu
Thông tin xuất bản: (2023) -
A combined 2-D and 3-D QSAR modeling, molecular docking study, design, and pharmacokinetic profiling of some arylimidamide-azole hybrids as superior L. donovani inhibitors
Thông tin tác giả:: Ugbe, Fabian Audu
Thông tin xuất bản: (2023) -
Theoretical investigation and design of some indole derivatives as potent β-glucuronidase inhibitors
Thông tin tác giả:: Ibrahim, Muhammad Tukur
Thông tin xuất bản: (2021) -
Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents
Thông tin tác giả:: Abdullahi, Sagiru Hamza
Thông tin xuất bản: (2023) -
QSAR, molecular docking studies, ligand-based design and pharmacokinetic analysis on Maternal Embryonic Leucine Zipper Kinase (MELK) inhibitors as potential anti-triple-negative breast cancer (MDA-MB-231 cell line) drug compounds
Thông tin tác giả:: Lawal, Hadiza Abdulrahman
Thông tin xuất bản: (2023)